secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001835268-25-000013
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma reports FY2024 net loss $15.6M; cash $93.7M into 2027
-----------------------------------------------------------------------

- Revenue $26.0M from Simcere license; no revenue in FY2023.
- R&D expense $29.3M (-$23.7M YoY) as Phase 2b asthma/atopic dermatitis trials completed.
- Net loss $15.6M ($0.28 EPS) vs $62.1M ($1.13) in FY2023.
- Phase 2 trials of rademikibart for acute asthma/COPD start Q2 2025; data expected H2 2026.
- CEO Barry Quart leads U.S.-centric shift; HQ relocated to San Diego, transition to domestic filer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000013/0001835268-25-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000013/cntb-20250331.htm
  HTML page:      https://secwatch.observer/filing/0001835268-25-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer